Type Whole antibody Target TNFRSF10B (TRAIL-R2) CAS Number 918127-53-4 | Source Humanized (from mouse) ATC code none ChemSpider none | |
 | ||
What does tigatuzumab mean
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed, Phase II trials for colorectal cancer and non-small cell lung cancer are running, and a study for ovarian cancer has been approved.
Contents
The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.
A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.
How to pronounce tigatuzumab
References
Tigatuzumab Wikipedia(Text) CC BY-SA